| | Business Summary | | Scios
Inc.
is
a
biopharmaceutical
company
developing
novel
treatments
for
cardiovascular
and
inflammatory
diseases.
The
Company
is
distinguished
by
its
disease-based
technology
platform,
which
integrates
expertise
in
protein
biology
with
computational
and
medicinal
chemistry
to
identify
novel
targets
and
protein-based
small
molecule
compounds
for
large
markets
with
insufficient
treatments.
Its
lead
product
candidates
include
Natrecor
(nesiritide)
and
its
p38
kinase
inhibitor,
SCIO-469. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Scios
discovers,
develops,
manufactures
and
commercializes
novel
human
therapeutics
based
upon
its
capabilities
in
both
protein-based
and
small-molecule
drug
discovery
and
development.
For
the
six
months
ended
6/30/01,
revenues
totaled
$17.2
million,
up
from
$6.3
million.
Net
loss
rose
13%
to
$22.5
million.
Revenues
reflect
a
gain
on
the
sale
of
marketing
rights.
Net
loss
reflects
increased
clinical
and
R&D
costs
related
to
Natrecor
and
kinase
inhibitor
programs. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Donald Rice, Ph.D., 61
Chairman | -- | -- | Richard Brewer, 49
Pres,
CEO | $806K | -- | David Gryska, 44
CFO,
Sr. VP-Fin. | 336K | -- | John Newman, 50
Sr.
VP, Gen. Counsel and Sec. | 290K | $390K | Thomas Feldman, 50
VP
of Sales and Marketing | -- | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/s/scio.gif)